Today: 7 February 2026
Subscribe

NVIDIA 2025: Dominating the AI Boom – Company Overview, Key Segments, Competition, and Future Outlook

Nvidia (NVDA) Stock Today: SoftBank Exits $5.8B Stake, CoreWeave Cuts Outlook; NVDA Slips Ahead of Nov. 19 Earnings — November 11, 2025

Updated: November 11, 2025 — U.S. market close Key Takeaways NVDA Price Action Today (11/11/2025) Nvidia closed at $194.38, down $4.67 (-2.35%) from Monday’s close of $199.05. Intraday range: $191.30–$195.42 on ~125.25M shares traded. Prior close: $199.05; 52‑week range: $86.62–$212.19. Figures are based on official end‑of‑day data. Yahoo Finance+1 What Moved Nvidia Stock Today 1) SoftBank Sells Entire Nvidia Stake Japan’s SoftBank Group said it sold all 32.1 million Nvidia shares in October (~$5.8B) to fund Masayoshi Son’s AI ambitions, including the “Stargate” data‑center initiative and expanded commitments to OpenAI. The news weighed on NVDA and chip peers as traders
11 November 2025
··
Tesla’s Stock Skyrockets on AI Hype – Latest Price Jump, Earnings Shocks & Bold 2025 Forecasts

Tesla Stock Today (11/11/2025): TSLA Slips as China Sales Hit 3‑Year Low, Musk’s Form 4 Lands, and $60/Day Rentals Go Live

Updated November 11, 2025 Key Takeaways TSLA Price Action: What’s Moving the Tape Tesla shares edged lower on Tuesday, November 11, 2025, hovering near $439.6 in afternoon trading. The stock’s day range sat at $432.36–$442.49, within a 52‑week band of $214.25–$488.54. With U.S. bond markets closed for Veterans Day and equities open, liquidity is thinner than usual, which can magnify reactions to headline risk. Broader tech sentiment was mixed as investors re‑assessed AI valuations. Reuters+2Reuters+2 The Big Tesla Headlines Today (11/11/2025) 1) China Sales Hit a Three‑Year Low New China Passenger Car Association data—reported by Reuters—show Tesla’s October China sales
11 November 2025
·
Microsoft Stock Soars on AI and Cloud Frenzy – Analysts Eye $600+ Price Targets

Microsoft (MSFT) Stock Today — Nov. 11, 2025: Shares Edge Higher as $10B Portugal AI Hub, Patch Tuesday Fixes and New Enterprise AI Deals Dominate Headlines

Updated Nov. 11, 2025 Key takeaways Market snapshot: MSFT price action Microsoft stock traded modestly higher on Tuesday, recently around $508.68, up $2.91 (~0.6%) versus the prior close. The session’s high/low printed near $509.54/$502.44, with intraday volume just under 17 million shares by late trade. Microsoft’s market capitalization hovered near $3.85 trillion, with a P/E of roughly 36.7 on trailing EPS of about $14.06. (All figures as of 21:40 UTC.) The news driving MSFT today Microsoft commits ~$10B to a European AI hub in Portugal Microsoft said it will invest $10 billion over the next few years in AI infrastructure
11 November 2025
·
Apple Stock Today (AAPL) — 11/11/2025: Shares Climb as AI-Spending Discipline Wins Fans; Dividend Arrives This Week

Apple Stock Today (AAPL) — 11/11/2025: Shares Climb as AI-Spending Discipline Wins Fans; Dividend Arrives This Week

Summary: Apple stock pushed higher on Tuesday, November 11, 2025, trading around $275 and up roughly 2% on the day. The move keeps AAPL within sight of its 52‑week high as investors reward Apple’s comparatively restrained AI spending and weigh fresh headlines about an iPhone Air sequel delay and this week’s quarterly dividend payment. As of today, Apple’s market cap is near $4.0 trillion, with an intraday range of $269.80–$275.91 and a 52‑week range of $169.21–$277.32, according to LSEG/Reuters data. Reuters Why AAPL is up today 1) “Less is more” on AI capexA Bloomberg analysis published today (syndicated by the
11 November 2025
···
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts

Published: November 11, 2025 Moderna, Inc. (NASDAQ: MRNA) drew multiple analyst headlines today as Wall Street recalibrated views in the wake of last week’s earnings and ongoing cost‑cutting. UBS highlighted potential 2026 upside on pipeline and expense discipline; Redburn Atlantic trimmed its price target; and Bernstein reiterated a neutral stance. Shares traded higher during the U.S. session alongside the commentary. MarketScreener+2MarketScreener+2 Today’s key headlines Stock move: By mid‑session, MRNA traded notably higher—around the mid‑single digits—amid the day’s analyst chatter. Investing.com Why these calls matter Investors are still digesting Q3 2025 results from November 6, when Moderna posted a narrower‑than‑expected loss
11 November 2025
·
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside

Viking Therapeutics (VKTX) on Nov. 11, 2025: Stifel Fireside Chat Today, Fresh VK2735 Obesity Data From ObesityWeek, and Phase 3 VANQUISH Progress

Published: November 11, 2025 Viking Therapeutics, Inc. (NASDAQ: VKTX) steps into the spotlight today with a scheduled fireside chat at the Stifel 2025 Healthcare Conference in New York (4:40–5:10 p.m. ET). The appearance comes on the heels of new clinical analyses from ObesityWeek® 2025 and an October corporate update outlining steady Phase 3 progress for its lead obesity candidate, VK2735. Viking Therapeutics InvestorRoom What’s happening today (Nov. 11) Viking’s management will host a fireside chat and hold 1×1 investor meetings at Stifel’s conference, part of a busy November investor-relations calendar that also includes a corporate presentation at the Jefferies 2025
11 November 2025
AppLovin (APP) soars ~7% after blowout Q3 2025: revenue up 68%, buyback boosted by $3.2B, and Wedbush lifts price target to $800

AppLovin (APP) Slides on 11/11/2025 as Citi Trims Target; SEC Overhang Persists While Q3 Blowout and Axon Rollout Stay in Focus

Published: November 11, 2025 What’s new today AppLovin Corporation (NASDAQ: APP) fell sharply in Tuesday trading, down roughly 7%–9% intraday to around $595–$605 as investors took profits following last week’s earnings pop and digested fresh sell‑side revisions. Real‑time market pages showed APP off more than 7% by early afternoon U.S. time. Reuters+1 Citigroup nudged its 12‑month price target down to $820 from $850 while maintaining a Buy rating, a modest recalibration after the stock’s torrid run into and after Q3 results. MarketScreener Trade press continued to frame AppLovin as an AI‑powered ad‑tech winner relative to peers, with Digiday’s Tuesday Ad
11 November 2025
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Today — Nov. 11, 2025: $10B Metsera Deal Nears Vote, Oncology Game Plan Expands, Shares Rise

Updated Nov. 11, 2025 Key takeaways Where the Metsera deal stands today Pfizer has agreed to acquire Metsera on final terms worth up to $10 billion, paying $65.60 in cash per share plus up to $20.65 per share in CVRs (maximum $86.25 per share). The structure, which Metsera’s board deemed superior on value and certainty of closing, is expected to go to a shareholder vote on Nov. 13 before closing. Reuters+1 While Novo Nordisk pushed the bidding to similar headline value, meticulous antitrust calculus tipped the field. Reuters Breakingviews reports that FTC outreach helped steer Metsera toward Pfizer; coupled with
11 November 2025
··
Leifras (NASDAQ: LFS) Rockets on November 11, 2025: Top Gainer Status, Quiet‑Period Countdown, and What’s Driving the Surge

Leifras (NASDAQ: LFS) Rockets on November 11, 2025: Top Gainer Status, Quiet‑Period Countdown, and What’s Driving the Surge

Leifras (LFS) ripped higher on Nov. 11, 2025, topping U.S. gainers as its IPO quiet period nears an end. Here’s what changed today—and what to watch next. Key takeaways What happened today (Tuesday, November 11, 2025) Shares of Leifras Co., Ltd. (NASDAQ: LFS) exploded higher, finishing the regular session as the No. 1 gainer across U.S. stocks tracked by StockAnalysis’ “Gainers Today,” up ~577% to $11.37 on ~31.6 million shares traded. The same price and percentage gain appeared on MarketBeat’s LFS page “as of 04:00 PM Eastern,” confirming the dramatic late‑day move. StockAnalysis+1 The spike unfolded after a volatile morning:
11 November 2025
·
FedEx (FDX) Jumps as CFO Signals Stronger Q2 Profit; Holiday Webcast Highlights, Veterans Day Operations, and New APAC–Europe Trade Insights — Nov. 11, 2025

FedEx (FDX) Jumps as CFO Signals Stronger Q2 Profit; Holiday Webcast Highlights, Veterans Day Operations, and New APAC–Europe Trade Insights — Nov. 11, 2025

Published: November 11, 2025 Key Takeaways FedEx Lifts Near‑Term Profit Outlook; Stock Rallies FedEx Corporation (NYSE: FDX) told investors today it expects adjusted earnings in its fiscal second quarter (ending Nov. 30) to come in above last year’s $4.05 per share—a level that also sits ahead of the ~$4.02 average analyst estimate referenced by Bloomberg data. The upbeat signal helped send FDX shares up roughly 5% intraday. Investing.com Speaking at an industry conference, the company also acknowledged potential cost and capacity headwinds tied to the ongoing grounding of MD‑11 freighters industry‑wide in the wake of last week’s UPS accident, though
11 November 2025
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Rallies on Nov. 11, 2025: FDA Approves New Keytruda Companion Diagnostic; Fresh SITC Combo Data, and Dow Momentum

Published: November 11, 2025 At a glance (today) Market move: MRK helps lead the Dow’s advance By early afternoon Tuesday, Merck & Co. (NYSE: MRK) shares were up about 3.9%, helping lead the Dow Jones Industrial Average higher; Nike and Merck together contributed an estimated ~36 points to the index’s ~386‑point climb at that time. MarketWatch In a separate Data Talk update, MRK was up for a sixth straight session, putting it on pace for its longest winning streak since August and tracking toward its highest close since Oct. 1—contingent on late‑day trading. Morningstar Regulatory update: FDA okays Promega’s OncoMate®
11 November 2025
Novo Nordisk (NVO) Slashes Wegovy Price in India Up to 37% as Board Vote Nears; U.S. Access Deal Sets 2026 Shift — Nov. 11, 2025

Novo Nordisk (NVO) Slashes Wegovy Price in India Up to 37% as Board Vote Nears; U.S. Access Deal Sets 2026 Shift — Nov. 11, 2025

Novo Nordisk cuts Wegovy prices in India up to 37% and faces a pivotal board vote this week, as a U.S. pricing/access deal looms for 2026. Date: November 11, 2025 Key takeaways India: Wegovy gets markedly cheaper — and it’s about more than price Novo Nordisk cut Wegovy’s Indian list prices across the dose range, with the monthly 2.4 mg pack now at ₹16,400 (down from ₹24,389 at launch) and the 0.25 mg starter at ₹10,850 (from ₹16,260). The company confirmed the reductions amid a fast‑evolving obesity market in the country. Reuters updated its initial “up to 33%” reporting to
11 November 2025
1 … 2,214 2,215 2,216 2,217 2,218 … 2,716

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop